ANDA 91123, held by Orbion Pharmaceuticals. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 91123 (Venlafaxine Hydrochloride), held by Orbion Pharmaceuticals, was first approved by FDA on Jul 11, 2011, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 11, 2011 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 37.5MG BASE ยท capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 75MG BASE ยท capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 150MG BASE ยท capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Feb 2, 2016 | Supplement 4Labeling ยท Standard review | Approved | None posted |
| Feb 2, 2016 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Feb 2, 2016 | Supplement 6Labeling ยท Standard review | Approved | None posted |
| Jan 10, 2014 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Oct 16, 2012 | Supplement 2Labeling ยท Standard review | Approved | None posted |
| Jul 11, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters